Heiko Ihle is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on companies in the Metals and Mining industry. Prior to joining H.C. Wainwright, Mr. Ihle worked as a Senior Research Analyst at Euro Pacific Capital where his research was also focused on the Mining industry. Prior to that, Mr. Ihle worked at Gabelli & Company covering both the Industrials and E&C industries. Mr. Ihle also completed summer internships with Deutsche Bank on the foreign exchange trading desk and on fixed income sales, in New York and Germany, respectively.
Analyst: Andrew Fein
Analyst
Andrew Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart.
Analyst: Kevin Dede
Analyst
Kevin Dede is a Managing Director of Equity Research at H.C. Wainwright. Prior to joining H.C. Wainwright, Mr. Dede conducted over twenty years of institutional research covering different industries such as telecommunications food chain, heavy industry, retail, financial services, and almost all realms of technology. Mr. Dede began his career at Prudential Securities and successively worked for other sell-side investment banks such as Montgomery Securities, Merriman Curhan & Ford, and Auriga LLC.
Analyst: Amit Dayal
Analyst
Amit Dayal is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on small cap growth companies listed in the U.S. Prior to joining H.C. Wainwright, Mr. Dayal was both an advisor for and an investor in tech startups. Mr. Dayal was also a Senior Research Analyst at Rodman & Renshaw for seven years where his research focused on companies operating in emerging markets as well as small and mid-cap companies such as TMT (Technology Media Telecom), Clean Tech, Industrials and Consumer.
Analyst: Dr. Yi Chen, Ph.D.
AnalystDr. Yi Chen is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biotechnology and the pharmaceutical sectors. Dr. Chen’s research covers investment opportunities in the U.S. healthcare industry. Prior to joining H.C. Wainwright, Dr. Chen worked as an Associate Director of Equity Research at Aegis Capital Corp. and as a Research Associate at Morgan Joseph TriArtisan, LLC. Dr. Chen also worked as a Trading Associate at Zhang Capital Management, a New York-based buy-side fund. Prior to that, Dr. Chen was a Research Associate at the City University of New York where his research focused primarily on protein signaling domains utilizing an RNA interference approach.
Analyst: Dr. Debjit Chattopadhyay
Analyst
Dr. Debjit Chattopadhyay is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on biotechnology, specifically on gene therapy, immune-oncology, and rare diseases. Prior to joining H.C. Wainwright, Dr. Chattopadhyay has been a Wall Street Healthcare Analyst, on the sell-side, working for Janney Montgomery Scott, Roth Capital Partners, and Boenning & Scattergood. Most recently, Dr. Chattopadhyay worked as the Managing Director and the Head of Biotechnology at Janney Montgomery Scott.
Analyst: Vernon T. Bernardino
Analyst
Vernon T. Bernardino is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Specific therapeutic areas of interest include vascular diseases, gastrointestinal and autoimmune diseases, infectious diseases, metabolic and rare diseases. He possesses over 10 years of experience in the healthcare industry and over 12 years in sell-side and buy-side equity research. Prior to joining H.C. Wainwright, Mr. Bernardino was a healthcare equity research analyst at multiple Wall Street firms including Seaport Global Securities, B. Riley FBR, Rodman & Renshaw LLC, UBS Securities, and Nicholas Applegate Capital Management (now part of Allianz SE). For 2017, Mr. Bernardino was recognized by TipRanks as a Top 150 Wall Street analyst.
Analyst: Ed Arce
Analyst
Ed Arce is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biopharmaceutical and the specialty pharmaceutical sectors. In particular, Mr. Arce’s research covers investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies Mr. Arce has been involved in institutionally-focused healthcare research since 2005. Prior to joining H.C. Wainwright, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes working for MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
H. C. Wainwright & Co.
Analyst
H.C. Wainwright & Co. is one of the country’s oldest financial institutions. H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America. H.C. Wainwright & Co., is a full-service investment bank dedicated to providing corporate fiance, strategic and licensing advisory, research, sales & trading, and related services to pubic and private companies. H.C. Wainwright & Co. has been the leader in the CMPU (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transactions since 1998.
Release: SCWORX ALERT Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against SCWorx Corp. and Encourages Investors to Contact the Firm
Release1 May 2020
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased SCWorx Corp. (NASDAQ: WORX) securities between April 13, 2020 and April 17, 2020 (the “Class Period”). Investors have until June 29, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Article: Summit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright
Article - MediaSummit Therapeutics (SMMT) Receives a Buy from H.C. Wainwright
Austin Angelo
AnalystRatings, 1 May 2020
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today and set a price target of $4.00. The company’s shares closed last Thursday at $3.75.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.2% and a 41.9% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Collegium Pharmaceutical.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
Article - MediaH.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
Jason Carr
AnalystRatings, 1 May 2020
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $23.00.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Article - MediaH.C. Wainwright Sticks to Their Buy Rating for Pluristem (PSTI)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Pluristem (PSTI), with a price target of $15.50. The company’s shares closed last Thursday at $9.17.
According to TipRanks.com, Ramakanth is a 1-star analyst with an average return of -0.7% and a 36.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, IntelGenx Technologies, and Corvus Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: H.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
Article - MediaH.C. Wainwright Keeps a Buy Rating on CareDx (CDNA)
Christine Brown
SmarterAnalyst, 1 May 2020
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on CareDx (CDNA), with a price target of $40.00. The company’s shares closed last Thursday at $25.38.
According to TipRanks.com, Chen is a 5-star analyst with an average return of 14.1% and a 43.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Victim: Greg Manning
Victim - Individual
Greg Manning owns one of the world’s most important auction houses for stamps, Greg Manning Auctions, Inc. (GMAI), is also a major auctioneer of coins, sports cards, movie posters, comic books, and other specialty collectibles. Greg Manning does business across the price spectrum but focuses on high-end specialty markets where its expertise and customer service can serve to differentiate the company from the competition. The company has a strong presence in Europe and Asia through joint ventures in Spain and China.
